Mamaearth IPO: During Mamaearth’s pre-IPO conference, commenting on the reduction in IPO size, one of the bankers clarified that the management team believes that at this point in time, the stated primary funding would be sufficient to support the company’s growth. He highlighted that the move reinstates the startup’s capital-efficient business model.
Glenmark Pharmaceuticals has entered into a share purchase agreement with Nirma Limited to divest a 75% stake in Glenmark Lifesciences at a price of Rs 615 per share.
As we cross the half-year mark, the Sensex stock market index reached an all-time high of 65,240.57 on the first day of market opening in July. All-time highs once again reiterate the Indian growth story and the resilience of the Indian .